When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13754 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540641209352192 |
|---|---|
| author | Pietro Paolo Vitiello Nadia Saoudi González Alberto Bardelli |
| author_facet | Pietro Paolo Vitiello Nadia Saoudi González Alberto Bardelli |
| author_sort | Pietro Paolo Vitiello |
| collection | DOAJ |
| description | The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical testing of such agents clashed with intrinsic and acquired resistance, greatly limiting their therapeutic value. However, a better understanding of the biology of the EGFR signaling pathway in CRC, coupled with the development of liquid biopsy methodologies to study cancer evolution in real time, fostered the clinical refinement of anti‐EGFR treatment in CRC. Such a workflow, based on the co‐evolution of biology knowledge and clinical development, allowed to couple the discovery of relevant therapy resistance mechanisms to the development of strategies to bypass this resistance. A broader application of this paradigm could prove successful and create an effective shortcut between the bench and the bedside for treatment strategies other than targeted therapy. |
| format | Article |
| id | doaj-art-fc99f7dc970b4d6e90ce7ccaa149e935 |
| institution | Kabale University |
| issn | 1574-7891 1878-0261 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj-art-fc99f7dc970b4d6e90ce7ccaa149e9352025-02-04T17:30:20ZengWileyMolecular Oncology1574-78911878-02612025-02-0119226727010.1002/1878-0261.13754When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancerPietro Paolo Vitiello0Nadia Saoudi González1Alberto Bardelli2Department of Oncology University of Torino ItalyIFOM ETS – The AIRC Institute of Molecular Oncology Milan ItalyDepartment of Oncology University of Torino ItalyThe discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical testing of such agents clashed with intrinsic and acquired resistance, greatly limiting their therapeutic value. However, a better understanding of the biology of the EGFR signaling pathway in CRC, coupled with the development of liquid biopsy methodologies to study cancer evolution in real time, fostered the clinical refinement of anti‐EGFR treatment in CRC. Such a workflow, based on the co‐evolution of biology knowledge and clinical development, allowed to couple the discovery of relevant therapy resistance mechanisms to the development of strategies to bypass this resistance. A broader application of this paradigm could prove successful and create an effective shortcut between the bench and the bedside for treatment strategies other than targeted therapy.https://doi.org/10.1002/1878-0261.13754precision medicinecolorectal cancerEGFRdrug resistancetranslational research |
| spellingShingle | Pietro Paolo Vitiello Nadia Saoudi González Alberto Bardelli When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer Molecular Oncology precision medicine colorectal cancer EGFR drug resistance translational research |
| title | When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer |
| title_full | When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer |
| title_fullStr | When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer |
| title_full_unstemmed | When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer |
| title_short | When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer |
| title_sort | when molecular biology transforms clinical oncology the egfr journey in colorectal cancer |
| topic | precision medicine colorectal cancer EGFR drug resistance translational research |
| url | https://doi.org/10.1002/1878-0261.13754 |
| work_keys_str_mv | AT pietropaolovitiello whenmolecularbiologytransformsclinicaloncologytheegfrjourneyincolorectalcancer AT nadiasaoudigonzalez whenmolecularbiologytransformsclinicaloncologytheegfrjourneyincolorectalcancer AT albertobardelli whenmolecularbiologytransformsclinicaloncologytheegfrjourneyincolorectalcancer |